[Retracted] In Silico Characterization of Growth Differentiation Factors as Inhibitors of TNF-Alpha and IL-6 in Immune-Mediated Inflammatory Disease Rheumatoid Arthritis

Table 2

Pharmacokinetic parameters important for bioavailability of compounds drug-likeness properties of selected peptides.

Sr. No.	Peptides	Receptor	Molecular properties^†
			Mass (<500 D)	HBD (≤5)	HBA (≤10)	Log (<5)	Molar refractivity (40-130)	Violations
1	SAGP	IL-6	330.34	5	7	-2.32	81.15	0
2	AFDP	TNF-α	448.47	5	8	-0.75	115.86	0
3	AGPC	TNF-α	346.40	4	6	-1.58	87.91	0
4	TETV	TNF-α	448.47	10	8	-2.25	106.22	1
5	AQET	IL-6	447.44	8	10	-2.93	103.16	1
6	GSAG	IL-6	290.27	6	7	-2.92	64.83	1
7	ISMA	TNF-α	420.52	6	7	-0.93	106.07	1
8	ANPR	TNF-α	456.50	8	8	-3.21	116.03	1
9	DGSP	IL-6	374.35	6	9	-2.95	87.73	1

HBD: hydrogen bond donors; HBA: hydrogen bond acceptors; log : the logarithm of octanol/water partition coefficient.